Investment in innovative solutions for active healing through orthobiologics
Coordinated by INSERM (Institut National de la Santé et de la Recherche Médicale) and with the support of the E.U., the REBORNE Program sought to establish the feasibility, relevance and efficacy of the association of MBCP+™*, a synthetic bone graft manufactured by Biomatlante made from MBCP™ Technology, and Mesenchymal Stem Cells (MSCs)1.
REBORNE was a 12 multi-center clinical trials over 8 European countries using advanced biomaterials and cells from autologous sources, as human mesenchymal stem cells from bone marrow, offering great potential for active bone regeneration. Biomatlante successfully went through a stringent selection process, after three years of experiences with the support of ANR (Agence Nationale de la Recherche)², prior to becoming the partner of choice of the European consortium as supplier of the bone graft matrix. A large consortium of 24 participants, with world class laboratories and GMP-cells manufacturing facilities and hospitals, collaborated to reach these ambitious clinical goals.
This program demonstrated the efficacy of expanded MSCs combined with the osteogenic matrix MBCP™ technology for bone tissue engineering in bone regeneration, both from a regulatory, scientific and clinical standpoint. The Reborne project demonstrated the osteogenic and osteoinductive properties of the association of MSCs and MBCP™ Technology3,4,5,6,7 with a high rate of clinical success, particularly in the treatment of long bone non-unions (92%).
Building on these successes, Reborne has now been extended to attempt to provide the same clinical excellence at an affordable price by combining the same MBCP™ Technology matrix with autologous concentrated bone marrow aspirate. Clinical trials are expected to begin in the next few months.
Regenerating Bone defects using New biomedical Engineering approaches REBORNE (7th EC project HEALTH 20091.4.2-241879)